QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure

Background: Patients resuscitated from ventricular tachyarrhythmias benefit from implantable cardioverter-defibrillators (ICDs) as opposed to medical treatment. Patients with increased QRS duration receiving an ICD in the presence of heart failure are at greatest risk of cardiac death and benefit mo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British heart journal 2003-10, Vol.89 (10), p.1157-1162
Hauptverfasser: Bode-Schnurbus, L, Böcker, D, Block, M, Gradaus, R, Heinecke, A, Breithardt, G, Borggrefe, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1162
container_issue 10
container_start_page 1157
container_title British heart journal
container_volume 89
creator Bode-Schnurbus, L
Böcker, D
Block, M
Gradaus, R
Heinecke, A
Breithardt, G
Borggrefe, M
description Background: Patients resuscitated from ventricular tachyarrhythmias benefit from implantable cardioverter-defibrillators (ICDs) as opposed to medical treatment. Patients with increased QRS duration receiving an ICD in the presence of heart failure are at greatest risk of cardiac death and benefit most from ICD therapy. Objective: To determine whether an increased QRS duration predicts cardiac mortality in ICD recipients. Design: Consecutive patients with heart failure in New York Heart Association functional class III were grouped according to QRS duration (< 150 ms, n = 139, group 1; v ⩾ 150 ms, n = 26, group 2) and followed up for (mean (SD)) 23 (20) months. Patients: 165 patients were studied (80% men, 20% women); 73% had coronary artery disease and 18% had dilated cardiomyopathy. Their mean age was 62 (10) years and mean ejection fraction (EF) was 33 (14)%. They presented either with ventricular tachycardia (VT) or ventricular fibrillation (VF). Main outcome measures: Overall and cardiac mortality; recurrence rates of VT, fast VT, or VF. Results: Mean left ventricular EF did not differ between group 1 (33 (13)%) and group 2 (31 (15)%). Forty patients died (34 cardiac deaths). There was no difference in survival between patients with EF > 35% and ⩽ 35%. Cardiac mortality was significantly higher in group 2 than in group 1 (31.3% at 12 months and 46.6% at 24 months, v 9.5% at 12 months and 18.2% at 24 months, respectively; p = 0.04). The recurrence rate of VT was similar in both groups. Conclusions: Within subgroups at highest risk of cardiac death, QRS duration—a simple non-invasive index—predicts outcome in ICD recipients in the presence of heart failure.
doi_str_mv 10.1136/heart.89.10.1157
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1767911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A108785722</galeid><sourcerecordid>A108785722</sourcerecordid><originalsourceid>FETCH-LOGICAL-b601t-6a8be066d22765d5765ad06c9e4364c77876f044146eb0e5b991d8972988c54d3</originalsourceid><addsrcrecordid>eNqFktuL1DAUh4so7jr67pMERF-kY9I2Nx-EZbwtLIrrenkLaXo6k7FNatKq-98bp8OOyoIEknDyncvv5GTZfYKXhJTs6QZ0GJdCLncGym9kx6RiIi8w-XIz3UtKc4ZLfpTdiXGLMa6kYLezI1JITivMjjP9_vwDaqagR-vdM6RRtP3QAep1-AoBtT6gIUBjzWjdGhkdGqsN6n0YdWfHS2QdOl29QEPyBzdG9MOOG7QrC7XadlOAu9mtVncR7u3PRfbx1cuL1Zv87N3r09XJWV4zTMacaVEDZqwpCs5oQ9OmG8yMhKpkleFccNbiqkr6oMZAaylJIyQvpBCGVk25yJ7PcYep7qExqZygOzUEm7RcKq-t-vvF2Y1a---KcMZlaucie7wPEPy3CeKoehsNdJ124KeoeOomr8oygQ__Abd-Ci6JS7EE5pJLyhOVz9Rad6Csa33KatbgICX3DlqbzCcECy4oL4rEL6_h02qgt-ZaBzw7mOBjDNBeaSVY_R4PtfsHJeRs2NX04M8eHRz285CAR3tAR6O7NmhnbDxwlFAhMDmIs3GEn1fvaWgU4yWn6u2nlboQQpT8XKrPiX8y83W__X-ZvwDHQN_A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780797957</pqid></control><display><type>article</type><title>QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bode-Schnurbus, L ; Böcker, D ; Block, M ; Gradaus, R ; Heinecke, A ; Breithardt, G ; Borggrefe, M</creator><creatorcontrib>Bode-Schnurbus, L ; Böcker, D ; Block, M ; Gradaus, R ; Heinecke, A ; Breithardt, G ; Borggrefe, M</creatorcontrib><description>Background: Patients resuscitated from ventricular tachyarrhythmias benefit from implantable cardioverter-defibrillators (ICDs) as opposed to medical treatment. Patients with increased QRS duration receiving an ICD in the presence of heart failure are at greatest risk of cardiac death and benefit most from ICD therapy. Objective: To determine whether an increased QRS duration predicts cardiac mortality in ICD recipients. Design: Consecutive patients with heart failure in New York Heart Association functional class III were grouped according to QRS duration (&lt; 150 ms, n = 139, group 1; v ⩾ 150 ms, n = 26, group 2) and followed up for (mean (SD)) 23 (20) months. Patients: 165 patients were studied (80% men, 20% women); 73% had coronary artery disease and 18% had dilated cardiomyopathy. Their mean age was 62 (10) years and mean ejection fraction (EF) was 33 (14)%. They presented either with ventricular tachycardia (VT) or ventricular fibrillation (VF). Main outcome measures: Overall and cardiac mortality; recurrence rates of VT, fast VT, or VF. Results: Mean left ventricular EF did not differ between group 1 (33 (13)%) and group 2 (31 (15)%). Forty patients died (34 cardiac deaths). There was no difference in survival between patients with EF &gt; 35% and ⩽ 35%. Cardiac mortality was significantly higher in group 2 than in group 1 (31.3% at 12 months and 46.6% at 24 months, v 9.5% at 12 months and 18.2% at 24 months, respectively; p = 0.04). The recurrence rate of VT was similar in both groups. Conclusions: Within subgroups at highest risk of cardiac death, QRS duration—a simple non-invasive index—predicts outcome in ICD recipients in the presence of heart failure.</description><identifier>ISSN: 1355-6037</identifier><identifier>ISSN: 0007-0769</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heart.89.10.1157</identifier><identifier>PMID: 12975406</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Analysis ; antiarrhythmics versus implantable defibrillator trial ; arrhythmia ; AVID ; Biological and medical sciences ; Canadian implantable defibrillator study ; cardiac arrhythmia suppression trial ; Cardiac dysrhythmias ; Cardiac patients ; Cardiology. Vascular system ; Cardiovascular Medicine ; Care and treatment ; CAST ; CIDS ; Clinical outcomes ; Death, Sudden, Cardiac - prevention &amp; control ; Defibrillators, Implantable ; ejection fraction ; Electrocardiography ; Evaluation ; Female ; Germany ; global utilisation of streptokinase and t-PA for occluded coronary arteries ; GUSTO-I ; Heart ; Heart attacks ; Heart failure ; Heart Failure - mortality ; Heart Failure - physiopathology ; Heart Failure - therapy ; Humans ; ICD ; implantable cardioverter-defibrillator ; Implantable cardioverter-defibrillators ; MADIT ; Male ; Medical sciences ; Middle Aged ; Mortality ; multicenter automatic defibrillator implantation trial ; Patient outcomes ; Patients ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Recurrence ; Risk Factors ; Statistics ; Stroke Volume - physiology ; Survival Analysis ; Tachycardia ; ventricular fibrillation ; Ventricular Fibrillation - therapy ; ventricular tachycardia</subject><ispartof>British heart journal, 2003-10, Vol.89 (10), p.1157-1162</ispartof><rights>Copyright 2003 by Heart</rights><rights>2004 INIST-CNRS</rights><rights>COPYRIGHT 2003 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2003 Copyright 2003 by Heart</rights><rights>Copyright © Copyright 2003 by Heart 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b601t-6a8be066d22765d5765ad06c9e4364c77876f044146eb0e5b991d8972988c54d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767911/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767911/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15158801$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12975406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bode-Schnurbus, L</creatorcontrib><creatorcontrib>Böcker, D</creatorcontrib><creatorcontrib>Block, M</creatorcontrib><creatorcontrib>Gradaus, R</creatorcontrib><creatorcontrib>Heinecke, A</creatorcontrib><creatorcontrib>Breithardt, G</creatorcontrib><creatorcontrib>Borggrefe, M</creatorcontrib><title>QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure</title><title>British heart journal</title><addtitle>Heart</addtitle><description>Background: Patients resuscitated from ventricular tachyarrhythmias benefit from implantable cardioverter-defibrillators (ICDs) as opposed to medical treatment. Patients with increased QRS duration receiving an ICD in the presence of heart failure are at greatest risk of cardiac death and benefit most from ICD therapy. Objective: To determine whether an increased QRS duration predicts cardiac mortality in ICD recipients. Design: Consecutive patients with heart failure in New York Heart Association functional class III were grouped according to QRS duration (&lt; 150 ms, n = 139, group 1; v ⩾ 150 ms, n = 26, group 2) and followed up for (mean (SD)) 23 (20) months. Patients: 165 patients were studied (80% men, 20% women); 73% had coronary artery disease and 18% had dilated cardiomyopathy. Their mean age was 62 (10) years and mean ejection fraction (EF) was 33 (14)%. They presented either with ventricular tachycardia (VT) or ventricular fibrillation (VF). Main outcome measures: Overall and cardiac mortality; recurrence rates of VT, fast VT, or VF. Results: Mean left ventricular EF did not differ between group 1 (33 (13)%) and group 2 (31 (15)%). Forty patients died (34 cardiac deaths). There was no difference in survival between patients with EF &gt; 35% and ⩽ 35%. Cardiac mortality was significantly higher in group 2 than in group 1 (31.3% at 12 months and 46.6% at 24 months, v 9.5% at 12 months and 18.2% at 24 months, respectively; p = 0.04). The recurrence rate of VT was similar in both groups. Conclusions: Within subgroups at highest risk of cardiac death, QRS duration—a simple non-invasive index—predicts outcome in ICD recipients in the presence of heart failure.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>antiarrhythmics versus implantable defibrillator trial</subject><subject>arrhythmia</subject><subject>AVID</subject><subject>Biological and medical sciences</subject><subject>Canadian implantable defibrillator study</subject><subject>cardiac arrhythmia suppression trial</subject><subject>Cardiac dysrhythmias</subject><subject>Cardiac patients</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular Medicine</subject><subject>Care and treatment</subject><subject>CAST</subject><subject>CIDS</subject><subject>Clinical outcomes</subject><subject>Death, Sudden, Cardiac - prevention &amp; control</subject><subject>Defibrillators, Implantable</subject><subject>ejection fraction</subject><subject>Electrocardiography</subject><subject>Evaluation</subject><subject>Female</subject><subject>Germany</subject><subject>global utilisation of streptokinase and t-PA for occluded coronary arteries</subject><subject>GUSTO-I</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>ICD</subject><subject>implantable cardioverter-defibrillator</subject><subject>Implantable cardioverter-defibrillators</subject><subject>MADIT</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>multicenter automatic defibrillator implantation trial</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Statistics</subject><subject>Stroke Volume - physiology</subject><subject>Survival Analysis</subject><subject>Tachycardia</subject><subject>ventricular fibrillation</subject><subject>Ventricular Fibrillation - therapy</subject><subject>ventricular tachycardia</subject><issn>1355-6037</issn><issn>0007-0769</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFktuL1DAUh4so7jr67pMERF-kY9I2Nx-EZbwtLIrrenkLaXo6k7FNatKq-98bp8OOyoIEknDyncvv5GTZfYKXhJTs6QZ0GJdCLncGym9kx6RiIi8w-XIz3UtKc4ZLfpTdiXGLMa6kYLezI1JITivMjjP9_vwDaqagR-vdM6RRtP3QAep1-AoBtT6gIUBjzWjdGhkdGqsN6n0YdWfHS2QdOl29QEPyBzdG9MOOG7QrC7XadlOAu9mtVncR7u3PRfbx1cuL1Zv87N3r09XJWV4zTMacaVEDZqwpCs5oQ9OmG8yMhKpkleFccNbiqkr6oMZAaylJIyQvpBCGVk25yJ7PcYep7qExqZygOzUEm7RcKq-t-vvF2Y1a---KcMZlaucie7wPEPy3CeKoehsNdJ124KeoeOomr8oygQ__Abd-Ci6JS7EE5pJLyhOVz9Rad6Csa33KatbgICX3DlqbzCcECy4oL4rEL6_h02qgt-ZaBzw7mOBjDNBeaSVY_R4PtfsHJeRs2NX04M8eHRz285CAR3tAR6O7NmhnbDxwlFAhMDmIs3GEn1fvaWgU4yWn6u2nlboQQpT8XKrPiX8y83W__X-ZvwDHQN_A</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>Bode-Schnurbus, L</creator><creator>Böcker, D</creator><creator>Block, M</creator><creator>Gradaus, R</creator><creator>Heinecke, A</creator><creator>Breithardt, G</creator><creator>Borggrefe, M</creator><general>BMJ Publishing Group Ltd and British Cardiovascular Society</general><general>BMJ</general><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>Copyright 2003 by Heart</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20031001</creationdate><title>QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure</title><author>Bode-Schnurbus, L ; Böcker, D ; Block, M ; Gradaus, R ; Heinecke, A ; Breithardt, G ; Borggrefe, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b601t-6a8be066d22765d5765ad06c9e4364c77876f044146eb0e5b991d8972988c54d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>antiarrhythmics versus implantable defibrillator trial</topic><topic>arrhythmia</topic><topic>AVID</topic><topic>Biological and medical sciences</topic><topic>Canadian implantable defibrillator study</topic><topic>cardiac arrhythmia suppression trial</topic><topic>Cardiac dysrhythmias</topic><topic>Cardiac patients</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular Medicine</topic><topic>Care and treatment</topic><topic>CAST</topic><topic>CIDS</topic><topic>Clinical outcomes</topic><topic>Death, Sudden, Cardiac - prevention &amp; control</topic><topic>Defibrillators, Implantable</topic><topic>ejection fraction</topic><topic>Electrocardiography</topic><topic>Evaluation</topic><topic>Female</topic><topic>Germany</topic><topic>global utilisation of streptokinase and t-PA for occluded coronary arteries</topic><topic>GUSTO-I</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>ICD</topic><topic>implantable cardioverter-defibrillator</topic><topic>Implantable cardioverter-defibrillators</topic><topic>MADIT</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>multicenter automatic defibrillator implantation trial</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Statistics</topic><topic>Stroke Volume - physiology</topic><topic>Survival Analysis</topic><topic>Tachycardia</topic><topic>ventricular fibrillation</topic><topic>Ventricular Fibrillation - therapy</topic><topic>ventricular tachycardia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bode-Schnurbus, L</creatorcontrib><creatorcontrib>Böcker, D</creatorcontrib><creatorcontrib>Block, M</creatorcontrib><creatorcontrib>Gradaus, R</creatorcontrib><creatorcontrib>Heinecke, A</creatorcontrib><creatorcontrib>Breithardt, G</creatorcontrib><creatorcontrib>Borggrefe, M</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bode-Schnurbus, L</au><au>Böcker, D</au><au>Block, M</au><au>Gradaus, R</au><au>Heinecke, A</au><au>Breithardt, G</au><au>Borggrefe, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure</atitle><jtitle>British heart journal</jtitle><addtitle>Heart</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>89</volume><issue>10</issue><spage>1157</spage><epage>1162</epage><pages>1157-1162</pages><issn>1355-6037</issn><issn>0007-0769</issn><eissn>1468-201X</eissn><abstract>Background: Patients resuscitated from ventricular tachyarrhythmias benefit from implantable cardioverter-defibrillators (ICDs) as opposed to medical treatment. Patients with increased QRS duration receiving an ICD in the presence of heart failure are at greatest risk of cardiac death and benefit most from ICD therapy. Objective: To determine whether an increased QRS duration predicts cardiac mortality in ICD recipients. Design: Consecutive patients with heart failure in New York Heart Association functional class III were grouped according to QRS duration (&lt; 150 ms, n = 139, group 1; v ⩾ 150 ms, n = 26, group 2) and followed up for (mean (SD)) 23 (20) months. Patients: 165 patients were studied (80% men, 20% women); 73% had coronary artery disease and 18% had dilated cardiomyopathy. Their mean age was 62 (10) years and mean ejection fraction (EF) was 33 (14)%. They presented either with ventricular tachycardia (VT) or ventricular fibrillation (VF). Main outcome measures: Overall and cardiac mortality; recurrence rates of VT, fast VT, or VF. Results: Mean left ventricular EF did not differ between group 1 (33 (13)%) and group 2 (31 (15)%). Forty patients died (34 cardiac deaths). There was no difference in survival between patients with EF &gt; 35% and ⩽ 35%. Cardiac mortality was significantly higher in group 2 than in group 1 (31.3% at 12 months and 46.6% at 24 months, v 9.5% at 12 months and 18.2% at 24 months, respectively; p = 0.04). The recurrence rate of VT was similar in both groups. Conclusions: Within subgroups at highest risk of cardiac death, QRS duration—a simple non-invasive index—predicts outcome in ICD recipients in the presence of heart failure.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Cardiovascular Society</pub><pmid>12975406</pmid><doi>10.1136/heart.89.10.1157</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1355-6037
ispartof British heart journal, 2003-10, Vol.89 (10), p.1157-1162
issn 1355-6037
0007-0769
1468-201X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1767911
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Adolescent
Adult
Aged
Aged, 80 and over
Analysis
antiarrhythmics versus implantable defibrillator trial
arrhythmia
AVID
Biological and medical sciences
Canadian implantable defibrillator study
cardiac arrhythmia suppression trial
Cardiac dysrhythmias
Cardiac patients
Cardiology. Vascular system
Cardiovascular Medicine
Care and treatment
CAST
CIDS
Clinical outcomes
Death, Sudden, Cardiac - prevention & control
Defibrillators, Implantable
ejection fraction
Electrocardiography
Evaluation
Female
Germany
global utilisation of streptokinase and t-PA for occluded coronary arteries
GUSTO-I
Heart
Heart attacks
Heart failure
Heart Failure - mortality
Heart Failure - physiopathology
Heart Failure - therapy
Humans
ICD
implantable cardioverter-defibrillator
Implantable cardioverter-defibrillators
MADIT
Male
Medical sciences
Middle Aged
Mortality
multicenter automatic defibrillator implantation trial
Patient outcomes
Patients
Predictive Value of Tests
Prognosis
Prospective Studies
Recurrence
Risk Factors
Statistics
Stroke Volume - physiology
Survival Analysis
Tachycardia
ventricular fibrillation
Ventricular Fibrillation - therapy
ventricular tachycardia
title QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A09%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=QRS%20duration:%20a%20simple%20marker%20for%20predicting%20cardiac%20mortality%20in%20ICD%20patients%20with%20heart%20failure&rft.jtitle=British%20heart%20journal&rft.au=Bode-Schnurbus,%20L&rft.date=2003-10-01&rft.volume=89&rft.issue=10&rft.spage=1157&rft.epage=1162&rft.pages=1157-1162&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heart.89.10.1157&rft_dat=%3Cgale_pubme%3EA108785722%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780797957&rft_id=info:pmid/12975406&rft_galeid=A108785722&rfr_iscdi=true